EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?

Anna Skwarska, Marina Konopleva

Cancer Cell · 2026-08 · 44 (8) · 1525-1532

DOI: 10.1016/j.ccell.2026.07.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-08. Verfasst von Anna Skwarska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Oncology), Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Drug Resistance, Neoplasm, Leukemia, Myeloid, Acute. Die Arbeit nennt 15 Literaturangaben. Gefördert von: V Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The BCL-2 inhibitor venetoclax has transformed outcomes for older or frail patients with acute myeloid leukemia (AML), and its resistance mechanisms are becoming better defined, including compensatory and lineage-associated switches toward MCL-1 or BCL-xL dependence, oncogenic signaling activation, blast phenotype, and differentiation stage. Additional putative mechanisms-such as emerging BAX mutations, mitochondrial structure remodeling, integrated stress response, and metabolic adaptations, including enhanced amino acid uptake and fatty acid oxidation to sustain oxidative phosphorylation-require further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesDrug Resistance, NeoplasmLeukemia, Myeloid, AcuteProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsHumansAnimalsSignal TransductionMutation

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesProto-Oncogene Proteins c-bcl-2Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine (Oncology), Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Department of Medicine (Oncology), Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: marina.konopleva@einsteinmed.edu.

Förderung

  • V Foundation

Zitieren

APA

Skwarska, A., & Konopleva, M. (2026). Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?. Cancer Cell, 44(8), 1525-1532. https://doi.org/10.1016/j.ccell.2026.07.004

Vancouver

Skwarska A, Konopleva M. Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?. Cancer Cell. 2026;44(8):1525-1532. doi:10.1016/j.ccell.2026.07.004

BibTeX
@article{Skwarska2026,
  author = {Skwarska, Anna and Konopleva, Marina},
  title = {Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {8},
  pages = {1525--1532},
  doi = {10.1016/j.ccell.2026.07.004}
}
Kostenlos starten →